M
Michael Weller
Researcher at University of Zurich
Publications - 1241
Citations - 112064
Michael Weller is an academic researcher from University of Zurich. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 134, co-authored 1105 publications receiving 91874 citations. Previous affiliations of Michael Weller include Johns Hopkins University & Medical University of Vienna.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
DNA methylation-based classification of central nervous system tumours
David Capper,David Capper,David Capper,David T.W. Jones,Martin Sill,Volker Hovestadt,Daniel Schrimpf,Daniel Schrimpf,Dominik Sturm,Dominik Sturm,Christian Koelsche,Christian Koelsche,Felix Sahm,Felix Sahm,Lukas Chavez,David E. Reuss,David E. Reuss,Annekathrin Kratz,Annekathrin Kratz,Annika K. Wefers,Annika K. Wefers,Kristin Huang,Kristin Huang,Kristian W. Pajtler,Kristian W. Pajtler,Leonille Schweizer,Leonille Schweizer,Damian Stichel,Damian Stichel,Adriana Olar,Nils W. Engel,Nils W. Engel,Kerstin Lindenberg,Patrick N. Harter,Patrick N. Harter,Anne K. Braczynski,Anne K. Braczynski,Karl H. Plate,Karl H. Plate,Hildegard Dohmen,Boyan K. Garvalov,Roland Coras,Annett Hölsken,Ekkehard Hewer,Melanie Bewerunge-Hudler,Matthias Schick,Roger Fischer,Rudi Beschorner,Jens Schittenhelm,Ori Staszewski,Khalida Wani,Pascale Varlet,Mélanie Pagès,Petra Temming,Dietmar R. Lohmann,Florian Selt,Florian Selt,Hendrik Witt,Hendrik Witt,Till Milde,Till Milde,Olaf Witt,Olaf Witt,Eleonora Aronica,Felice Giangaspero,Elisabeth J. Rushing,Wolfram Scheurlen,Christoph Geisenberger,Christoph Geisenberger,Fausto J. Rodriguez,Albert J. Becker,Matthias Preusser,Christine Haberler,Rolf Bjerkvig,Jane Cryan,Michael A. Farrell,Martina Deckert,Jürgen Hench,Stephan Frank,Jonathan Serrano,Kasthuri Kannan,Aristotelis Tsirigos,Wolfgang Brück,Silvia Hofer,Stefanie Brehmer,Marcel Seiz-Rosenhagen,Daniel Hänggi,Volkmar Hans,Stephanie Rozsnoki,Jordan R. Hansford,Patricia Kohlhof,Bjarne Winther Kristensen,Matt Lechner,Beatriz Lopes,Christian Mawrin,Ralf Ketter,Andreas E. Kulozik,Ziad Khatib,Frank L. Heppner,Arend Koch,Anne Jouvet,Catherine Keohane,Helmut Mühleisen,Wolf Mueller,Ute Pohl,Marco Prinz,Axel Benner,Marc Zapatka,Nicholas G. Gottardo,Nicholas G. Gottardo,Pablo Hernáiz Driever,Christof M. Kramm,Hermann L. Müller,Stefan Rutkowski,Katja von Hoff,Michael C. Frühwald,Astrid Gnekow,Gudrun Fleischhack,Stephan Tippelt,Gabriele Calaminus,Camelia-Maria Monoranu,Arie Perry,Chris Jones,Thomas S. Jacques,Bernhard Radlwimmer,Marco Gessi,Torsten Pietsch,Johannes Schramm,Gabriele Schackert,Manfred Westphal,Guido Reifenberger,Guido Reifenberger,Pieter Wesseling,Pieter Wesseling,Michael Weller,Vincent Peter Collins,Ingmar Blümcke,Martin Bendszus,Jürgen Debus,Annie Huang,Nada Jabado,Paul A. Northcott,Werner Paulus,Amar Gajjar,Giles W. Robinson,Michael D. Taylor,Zane Jaunmuktane,Marina Ryzhova,Michael Platten,Andreas Unterberg,Wolfgang Wick,Matthias A. Karajannis,Michel Mittelbronn,Till Acker,Christian Hartmann,Kenneth Aldape,Ulrich Schüller,Ulrich Schüller,Rolf Buslei,Peter Lichter,Marcel Kool,Christel Herold-Mende,David W. Ellison,Martin Hasselblatt,Matija Snuderl,Sebastian Brandner,Andrey Korshunov,Andrey Korshunov,Andreas von Deimling,Andreas von Deimling,Stefan M. Pfister,Stefan M. Pfister +171 more
TL;DR: This work presents a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and shows that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods.
Journal ArticleDOI
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz,Ulrike M. Litzenburger,Ulrike M. Litzenburger,Felix Sahm,Martina Ott,Isabel Tritschler,Saskia Trump,Theresa Schumacher,Theresa Schumacher,Leonie Jestaedt,Dieter Schrenk,Michael Weller,Manfred Jugold,Gilles J. Guillemin,Christine L. Miller,Christian Lutz,Bernhard Radlwimmer,Irina Lehmann,Andreas von Deimling,Wolfgang Wick,Michael Platten +20 more
TL;DR: Evidence is provided for a previously unidentified pathophysiological function of the AHR that is constitutively generated by human tumours via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-derived Trp-degrading enzyme not yet implicated in cancer biology.